News | December 21, 2023
AGC invests US$ 348 million to expand its biopharmaceutical CDMO capability
Development services for gene and cell therapies is planned to begin first in 2025
Development services for gene and cell therapies is planned to begin first in 2025
Clariant Healthcare highlighted Vitipure Meglumine LEX and VitiPure Superior at the recently concluded CPhI India
Granules Pharmaceuticals gets 5 observations from USFDA on completion of GMP inspection
Lacosamide is indicated to treat partial-onset seizures
10+ emerging markets, Japan & ANZ transition in final phase
Laurus Synthesis receives Form 483 with 5 observations from USFDA
Darunavir is a protease inhibitor antiviral medicine that prevents Human Immunodeficiency Virus (HIV-1) from multiplying in the body
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
New facility is part of Aptar Pharma’s global expansion program
Subscribe To Our Newsletter & Stay Updated
